--- title: "PAMA, Protecting Access to Medicare Act | MedTech Terms" description: "Law that revised Medicare pricing for clinical lab services. Plain-English Reimbursement definition for MedTech teams, with examples and related terms." lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/pama#term", "name": "Protecting Access to Medicare Act", "alternateName": "PAMA", "description": "PAMA (2014) requires CMS to set Clinical Laboratory Fee Schedule rates based on weighted-median private payer rates reported by clinical labs. Repeated reporting and rate cuts have pressured the IVD industry.", "url": "https://medtechterms.com/terms/pama", "termCode": "pama", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/pama#article", "headline": "PAMA, Protecting Access to Medicare Act", "description": "Law that revised Medicare pricing for clinical lab services.", "url": "https://medtechterms.com/terms/pama", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/pama" }, "about": { "@id": "https://medtechterms.com/terms/pama#term" }, "articleSection": "Reimbursement", "inLanguage": "en", "keywords": "Protecting Access to Medicare Act, PAMA, Reimbursement, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "AdvaMed - Payment & Coverage", "url": "https://www.advamed.org/our-work/", "publisher": { "@type": "Organization", "name": "AdvaMed" } }, { "@type": "CreativeWork", "name": "AMA CPT Resources", "url": "https://www.ama-assn.org/practice-management/cpt", "publisher": { "@type": "Organization", "name": "AMA" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/ivd#term", "name": "In Vitro Diagnostics", "alternateName": "IVD", "url": "https://medtechterms.com/terms/ivd" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/molecular-diagnostics#term", "name": "Molecular Diagnostics", "url": "https://medtechterms.com/terms/molecular-diagnostics" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/ldt#term", "name": "Laboratory-Developed Test", "alternateName": "LDT", "url": "https://medtechterms.com/terms/ldt" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Reimbursement", "item": "https://medtechterms.com/terms?cat=Reimbursement" }, { "@type": "ListItem", "position": 4, "name": "Protecting Access to Medicare Act", "item": "https://medtechterms.com/terms/pama" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/pama#faq", "mainEntity": [ { "@type": "Question", "name": "What is the primary goal of PAMA regarding clinical laboratory payments?", "acceptedAnswer": { "@type": "Answer", "text": "PAMA's primary goal is to provide more accurate Medicare payment for clinical diagnostic laboratory tests by basing rates on data from private payers, aiming to reduce Medicare spending on these services." } }, { "@type": "Question", "name": "Which entities are most directly impacted by PAMA's reporting requirements?", "acceptedAnswer": { "@type": "Answer", "text": "Clinical laboratories that receive the majority of their Medicare revenues from the Clinical Laboratory Fee Schedule and meet specific revenue thresholds are primarily responsible for reporting private payer data under PAMA." } }, { "@type": "Question", "name": "How does PAMA affect In Vitro Diagnostic (IVD) manufacturers?", "acceptedAnswer": { "@type": "Answer", "text": "While PAMA directly regulates laboratories, IVD manufacturers are indirectly affected as reduced reimbursement for tests performed using their products can decrease demand or pressure pricing, impacting their market access strategies." } }, { "@type": "Question", "name": "Are there specific types of lab tests that PAMA particularly targets?", "acceptedAnswer": { "@type": "Answer", "text": "PAMA significantly impacts advanced diagnostic laboratory tests (ADLTs), for which a specific payment methodology and data reporting requirements apply, often leading to distinct reimbursement rates and pathways." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Reimbursement](/terms?cat=Reimbursement) 6. / 7. Protecting Access to Medicare Act [All terms](/terms) Reimbursement [Clinical Evidence](/ecosystems/clinical-evidence)[Hospital Buyer & Reimbursement](/ecosystems/hospital-buyer)PAMA # Protecting Access to Medicare Act Law that revised Medicare pricing for clinical lab services. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition PAMA (2014) requires CMS to set Clinical Laboratory Fee Schedule rates based on weighted-median private payer rates reported by clinical labs. Repeated reporting and rate cuts have pressured the [IVD](/terms/ivd) industry. What the regulation says The Protecting Access to Medicare Act (PAMA) of 2014, specifically Sections 216(a) and (b), mandates the Centers for Medicare & Medicaid Services (CMS) to revise the Clinical Laboratory Fee Schedule (CLFS) for laboratory tests. This revision involves basing payment rates on the weighted median of private payer rates, collected from applicable laboratories via data reporting, as detailed in 42 CFR 414.506. The intent is to align Medicare payment for laboratory services more closely with prices paid by private payers. ## What this means in practice Combined with FDA [LDT](/terms/ldt) oversight, PAMA reshapes [molecular diagnostics](/terms/molecular-diagnostics) economics. ## Examples - An In Vitro Diagnostic (IVD) manufacturer adjusts its product pricing strategy for a new molecular diagnostic test, anticipating lower reimbursement rates due to PAMA's impact on clinical laboratory payments. - A clinical laboratory establishes an internal data analytics team to accurately collect and report private payer rates for its high-volume tests to CMS, ensuring compliance with PAMA's reporting mandates. - A MedTech company developing an innovative liquid biopsy diagnostic conducts a thorough PAMA impact analysis, modeling potential Medicare reimbursement scenarios to inform its commercialization plan. Common pitfalls - • A common pitfall is underestimating the administrative burden and technical complexities associated with accurate data collection and reporting of private payer rates to CMS. - • Companies often fail to proactively model the financial impact of PAMA-driven rate reductions on their product portfolios and overall business strategy, leading to unexpected revenue losses. - • Misinterpreting the definitions of "applicable laboratory" or "advanced diagnostic laboratory test" (ADLT) can lead to non-compliance with reporting requirements or incorrect payment methodologies. - • Some organizations mistakenly believe that PAMA only affects clinical laboratories providing services, overlooking its downstream impact on IVD manufacturers whose products are used in those laboratories. - • Failure to maintain robust internal processes for auditing reported data can result in inaccuracies, potentially leading to CMS recoupment actions or penalties. ## Frequently asked questions What is the primary goal of PAMA regarding clinical laboratory payments? PAMA's primary goal is to provide more accurate Medicare payment for clinical diagnostic laboratory tests by basing rates on data from private payers, aiming to reduce Medicare spending on these services. Which entities are most directly impacted by PAMA's reporting requirements? How does PAMA affect In Vitro Diagnostic (IVD) manufacturers? Are there specific types of lab tests that PAMA particularly targets? ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Market Segments In Vitro Diagnostics(IVD) Tests performed on biological samples outside the body. ](/terms/ivd)[ Market Segments Laboratory-Developed Test(LDT) IVD designed, manufactured, and used within a single CLIA laboratory. ](/terms/ldt)[ Market Segments Molecular Diagnostics IVDs that detect nucleic acids - DNA or RNA - to diagnose disease. ](/terms/molecular-diagnostics) ### More in Reimbursement · Same category [ Reimbursement 340B Drug Pricing Program(340B) Federal program providing discounted drugs to safety-net providers. ](/terms/340b)[ Reimbursement Ambulatory Payment Classification(APC) The Medicare grouping system that determines hospital outpatient payment amounts under OPPS, analogous to MS-DRGs for inpatient. ](/terms/apc)[ Reimbursement ASC Site-of-Service Shift Migration of procedures from hospitals to ambulatory surgery centers. ](/terms/asc-shift)[ Reimbursement Budget Impact Model(BIM) Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon. ](/terms/budget-impact-model) Cited by Where this term appears across MedTech Terms. Ecosystems (2) - [Clinical Evidence](/ecosystems/clinical-evidence) - [Hospital Buyer & Reimbursement](/ecosystems/hospital-buyer) ## Primary references 2 sources Link health: 2 verified · last checked 2026-06-20 AdvaMed· 1 AMA· 1 1. [1 AdvaMed - Payment & Coverage Verified AdvaMed · advamed.org ](https://www.advamed.org/our-work/) 2. [2 AMA CPT Resources Verified AMA · ama-assn.org ](https://www.ama-assn.org/practice-management/cpt) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Need cybersecurity expertise on a connected-device launch? Blue Goat Cyber helps MedTech teams ship connected products that hospital security teams will actually procure. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Reimbursement Acronym PAMA Sources 2 Updated 5/5/2026 [Compare with another term](/compare?a=pama) Learn in 60 seconds Card Lesson Quiz Law that revised Medicare pricing for clinical lab services. - · Combined with FDA LDT oversight, PAMA reshapes molecular diagnostics economics. - · Repeated reporting and rate cuts have pressured the IVD industry. Remember this Watch out: A common pitfall is underestimating the administrative burden and technical complexities associated with accurate data collection and reporting of private payer rates to CMS. Related terms - [In Vitro Diagnostics(IVD) ](/terms/ivd) - [Molecular Diagnostics ](/terms/molecular-diagnostics) - [Laboratory-Developed Test(LDT) ](/terms/ldt) You may also need Auto-suggested from Reimbursement and shared keywords. - [New Technology Add-On Payment(NTAP) ](/terms/ntap) - [Proprietary Laboratory Analyses Codes(PLA) ](/terms/pla-codes) - [CMS IDE Coverage (Category A & B) ](/terms/ide-coverage) - [Coverage with Evidence Development(CED) ](/terms/ced) - [Health Economics and Outcomes Research(HEOR) ](/terms/heor) - [Inpatient Prospective Payment System(IPPS) ](/terms/ipps) [All Reimbursement terms](/terms?cat=Reimbursement) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)